Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants

By L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa and 2 more. Science, 2002

3,456 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/7dee504bbd1f94a93e3c5d3cb9e2d0fbd4581005

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Y. Hayakawa
2. M. Smyth
3. O. Ringdén

In Immunology

1. M. Smyth
2. L. Zitvogel
3. M. Caligiuri
4. É. Vivier
5. S. Ugolini
6. Peter Parham
7. D. Raulet
8. R. Vance

Citations in the corpus

• Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. (2005, background): “By contrast, infusions of pure CD56 CD3 NK cells should not impose that risk.(12) Most clinical studies of the therapeutic effects of NK cells have been performed in an autologous setting and have yielded only moderately promising results.”
• Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia (2016, background): “Analternative approach thatprovides the immunotherapeutic benefits of allogeneic HCTwithout severe toxicity is the adoptive transfer of allogeneic lymphocytes that mediate the “graft versus leukemia” effect.”
• Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity (2017, positive): “NK cells do not cause GVHD,(8, 9) and thus open opportunities to produce an off-the-shelf product for immediate clinical use.”
• Pre-activation with IL-12, IL-15, and IL-18 induces CD25 and a functional high affinity IL-2 receptor on human cytokine-induced memory-like NK cells (2014, background): “Initial reports in the MHC-haploidentical transplantation setting indicated that NK cells may be harnessed for graft-versusleukemia effects in the absence of graft-versus-host disease [9].”
• Natural killer cells and dendritic cells: rendezvous in abused tissues (2002, background): “Remarkably, this graft-versus-leukaemia (GVL) effect does not affect normal tissues that are usually attacked by the alloreactive T cells that mediate graft-versus-host disease (GVHD”
• Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. (2010, neutral): “Donor /recipient 80 (25) 144 (13) 92 (12) 52 (15)”